Cover Image

The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products

Nonalcoholic steatohepatitis (NASH) is a clinical syndrome with pathological changes that are similar to those of alcoholic hepatitis without a history of excessive alcohol consumption. It is a specific form of nonalcoholic fatty liver disease (NAFLD) that is characterized by hepatocyte inflammation...

Full description

Saved in:

Bibliographic Details
Main Authors:	Gaoxuan Shao (Author), Ying Liu (Author), Lu Lu (Author), Guangtao Zhang (Author), Wenjun Zhou (Author), Tao Wu (Author), Lei Wang (Author), Hanchen Xu (Author), Guang Ji (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

New insights into natural products that target the gut microbiota: Effects on the prevention and treatment of colorectal cancer
by: Lu Lu, et al.
Published: (2022)

A smart dual-drug nanosystem based on co-assembly of plant and food-derived natural products for synergistic HCC immunotherapy
by: Bingchen Zhang, et al.
Published: (2021)

Salidroside may target PPARα to exert preventive and therapeutic activities on NASH
by: Xueru Chu, et al.
Published: (2024)

Leptin induces muscle wasting in a zebrafish kras-driven hepatocellular carcinoma (HCC) model
by: Qiqi Yang, et al.
Published: (2019)

Mechanism of sorafenib resistance associated with ferroptosis in HCC
by: Lingling Guo, et al.
Published: (2023)

Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
by: Brian Finan, et al.
Published: (2021)

HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)
by: Wenhui Wang, et al.
Published: (2022)

Performance of HCC diagnosis in the KLCA-NCC guidelines: a closer look at MRI contrast agents and HCC imaging hallmarks
by: Ji Hye Min, et al.
Published: (2024)

Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment
by: Rui Han, et al.
Published: (2023)

Acacetin exerts antitumor effects on gastric cancer by targeting EGFR
by: Guangtao Zhang, et al.
Published: (2023)

Saroglitazar – A Potential Therapeutic Option in Treating NASH? [Letter]
by: Shuja SH, et al.
Published: (2021)

Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach
by: Paola Orlandi, et al.
Published: (2021)

NAShI AVTORY
by: -
Published: (2016)

NAShI AVTORY
by: -
Published: (2015)

NAShI AVTORY
by: -
Published: (2016)

NAShI AVTORY
by: -
Published: (2015)

NAShI AVTORY
by: -
Published: (2015)

Non-Alcoholic Steatohepatitis (NASH) – A Review of a Crowded Clinical Landscape, Driven by a Complex Disease
by: Fraile JM, et al.
Published: (2021)

TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
by: Jin Lei, et al.
Published: (2022)

Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores
by: Yan Huang, et al.
Published: (2022)

Sijunzi decoction granules in the prevention and treatment of recurrence of colorectal adenoma: Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
by: Wenjing Ni, et al.
Published: (2023)

NASH E OS PASTEIS
by: Alexandre Godinho Bertoncello, et al.
Published: (2016)

NASH E OS PASTEIS
by: Alexandre Godinho Bertoncello, et al.
Published: (2016)

Cytochrome P450s in algae: Bioactive natural product biosynthesis and light-driven bioproduction
by: Shanmin Zheng, et al.
Published: (2022)

Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH
by: Leigh Goedeke, et al.
Published: (2021)

Elevated Serum Uric Acid is Associated With Poor Survival in Advanced HCC Patients and Febuxostat Improves Prognosis in HCC Rats
by: Le Wu, et al.
Published: (2021)

NASH and Systemic Complications From Basic to Clinical Research
Published: (2022)

Melatonin inhibits HCC progression through regulating the alternative splicing of NEMO
by: Lu Bai, et al.
Published: (2022)

The potential of mRNA vaccine in HCC treatment
by: Rui Han
Published: (2023)

Evolving Role for Pharmacotherapy in NAFLD/NASH
by: Suzanna L. Attia, et al.
Published: (2021)

Imaging biomarkers of NAFLD, NASH, and fibrosis
by: Veeral Ajmera, et al.
Published: (2021)

lncRNA MAGI2-AS3 Prevents the Development of HCC via Recruiting KDM1A and Promoting H3K4me2 Demethylation of the RACGAP1 Promoter
by: Jian Pu, et al.
Published: (2019)

SLC35B4 Stabilizes c-MYC Protein by O-GlcNAcylation in HCC
by: Tao Jiang, et al.
Published: (2022)

Bofutsushosan (Fangfengtongshengsan) improves early stages of NASH via the gut-liver axis in diabetes-induced NASH model mice
by: Mitsue Nishiyama, et al.
Published: (2024)

Extracellular vesicles in the HCC microenvironment: Implications for therapy and biomarkers
by: Le Cheng, et al.
Published: (2024)

Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?
by: Francesca Negri, et al.
Published: (2021)

Targeted inhibition of osteoclastogenesis reveals the pathogenesis and therapeutics of bone loss under sympathetic neurostress
by: Bingdong Sui, et al.
Published: (2022)

Therapeutic potential of natural products in schistosomiasis-associated liver fibrosis
by: Cuiling Liu, et al.
Published: (2024)

Mitochondrial dysfunction-targeting therapeutics of natural products in Parkinson's disease
by: Ting He, et al.
Published: (2023)

Editorial: New Insights Into Renal Fibrosis and Therapeutic Effects of Natural Products
by: Ying Xu, et al.
Published: (2022)